These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17383679)

  • 1. MS treatment: postmarketing studies.
    Montalban X
    J Neurol Sci; 2007 Aug; 259(1-2):42-5. PubMed ID: 17383679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.
    Wingerchuk DM
    Expert Rev Neurother; 2006 Mar; 6(3):333-46. PubMed ID: 16533138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
    Schwid SR; Panitch HS
    Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy in multiple sclerosis.
    Fernández O
    J Neurol Sci; 2007 Aug; 259(1-2):95-103. PubMed ID: 17507031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease.
    Siva A; Saip S; Altintas A; Jacob A; Keegan BM; Kantarci OH
    Mult Scler; 2009 Aug; 15(8):918-27. PubMed ID: 19667020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current evidence and therapeutic strategies for multiple sclerosis.
    Wingerchuk DM
    Semin Neurol; 2008 Feb; 28(1):56-68. PubMed ID: 18256987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shifting the paradigm toward earlier treatment of multiple sclerosis with interferon beta.
    Comi G
    Clin Ther; 2009 Jun; 31(6):1142-57. PubMed ID: 19695384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
    Lugaresi A
    Expert Opin Drug Deliv; 2009 Sep; 6(9):995-1002. PubMed ID: 19637982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What can be learned from open direct comparative trials in multiple sclerosis?
    Khan O
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of early interferon beta-1a therapy on conversion to multiple sclerosis in Iranian patients with a first demyelinating event.
    Pakdaman H; Sahraian MA; Fallah A; Pakdaman R; Ghareghozli K; Ghafarpour M; Rahimian E; Shirani A
    Acta Neurol Scand; 2007 Jun; 115(6):429-31. PubMed ID: 17511854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis.
    Shevchenko YL; Novik AA; Kuznetsov AN; Afanasiev BV; Lisukov IA; Kozlov VA; Rykavicin OA; Ionova TI; Melnichenko VY; Fedorenko DA; Kulagin AD; Shamanski SV; Ivanov RA; Gorodokin G
    Exp Hematol; 2008 Aug; 36(8):922-8. PubMed ID: 18468768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
    Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sclerosis: an update for oral health care providers.
    Fischer DJ; Epstein JB; Klasser G
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep; 108(3):318-27. PubMed ID: 19716502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis.
    Mirowska-Guzel D
    Immunopharmacol Immunotoxicol; 2009; 31(1):32-8. PubMed ID: 18792835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmarketing evidence of disease-modifying drugs in multiple sclerosis.
    Trojano M; Paolicelli D; Fuiani A; Pellegrini F; Iaffaldano P; Direnzo V; D'Onghia M
    Neurol Sci; 2008 Sep; 29 Suppl 2():S225-6. PubMed ID: 18690499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Postmarketing surveillance studies in community pharmacies].
    Nieber K; Lehmacher W
    Med Monatsschr Pharm; 2009 Aug; 32(8):301-6. PubMed ID: 19777737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natalizumab treatment in pediatric multiple sclerosis: a case report.
    Borriello G; Prosperini L; Luchetti A; Pozzilli C
    Eur J Paediatr Neurol; 2009 Jan; 13(1):67-71. PubMed ID: 18406645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recommendations for optimising the treatment of multiple sclerosis in Latin America].
    Cristiano E; Arcega R; Correale J; Gabbay AA; Lander-Delgado R; Macias-Islas MA; Palacios E; Patrucco L; Rivera-Olmos V; Soto A
    Rev Neurol; 2007 Apr 16-30; 44(8):494-8. PubMed ID: 17455164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.